Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal

Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.

Source: Pharmaceutical Technology, 2026-10-06. Third-party report, linked to its original publisher; IC360 has not independently verified it.